Alan D’Andrea

Company: Dana-Farber Cancer Institute

Job title: Director, Center for DNA Damage and Repair

Seminars:

What are the Unique Selling Points of USP1 for Synthetic Lethality? 2:45 pm

• Updates for novel selective USP1 inhibitors in BRCA1-deficient cells for patients who do not respond to PARP inhibitors • Exploring updates for molecules with ADME properties and PK profiles • Unearth data for potential monotherapy and combination therapies of USP1 inhibitorsRead more

day: Day One Track B PM